Efficacy and safety of Dalfaz in patients with symptoms of benign prostatic hyperplasia (seven years of observation)
- Authors: Pushkar' DY.1, Rasner PI1, Pushkar DY.1, Rasner PI1
-
Affiliations:
- Issue: No 16 (2009)
- Pages: 58-63
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278081
- ID: 278081
Cite item
Full Text
Abstract
The results of the study the effectiveness of long-term treatment with α-adrenoblocker Dalfaz (alfuzosin), which included 41 patients of benign prostatic hyperplasia (BPH), are presented. The study demonstrated the high safety of Dalfaz administration in patients with urination disorders. Dalfaz has received a good mark as a safe and high effective drug for prolonged drug therapy for BPH. The study confirmed the principal possibility of permanent Dalfaz administration in patients with benign prostatic hyperplasia for many years as first-line drugs for medication correction of urination disorders in patients with BPH.
References
- Roehrborn C. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008;101(Suppl. 3)17-21.
- Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004;45:411-19.
- Hutchison A, Farmer R, Verhamme et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 european countries. Eur Urol 2007;51:207-16.
- Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-88.
- Lukacs B, McCarthy C, Grande JC, and the QOL BPH Study Groupin General Practice. Long term quality of life in patients with with benign prostatic hypertrophy: preliminary results of a cohort survey of 7093 patients treated with alpha-1 blocker, alfuzosin. Eur Urol 1993;24(Suppl. 1):34-40.
- Lukacs B, grange JC, et al. Three year prospective study in 3228 clinical BPH patients treated with alfuzosin in general practice. Prostate Cancer and Prostatic Diseases 1998;5:276-83.
- Сивков А.В. Медикаментозная терапия доброкачественной гиперплазии предстательной железы. В кн. Доброкачественная гиперплазия предстательной железы / Под ред. Лопаткина Н.А. М., 1999. С. 91-116.
- Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 Guidelines on Assessment,Therapy and Follow-Up ofMen with Lower UrinaryTract Symptoms Suggestive of Benign Prostatic Obstruction (BPHGuidelines). Eur Urol 2004;46:547-54.
- Roehrborn C. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006;97:734-41.
- Vallancien G, Emberton M, Alcaraz F, et al Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice BJU 2008;101:847-52.
- Elhilali M, Emberton M, Matzkin H, Alf-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in "reallife" practice. BJU Int 2006;97:513-19.
- van Kerrebroec P, Jardin A, van Cangh P, et al. ALFORTI Study Group. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: openlabel extension study. Eur Urol 2002;41:54-60.
- Лоран О.Б., Вишневский Е.Л., Вишневский А.Е. Лечение расстройств мочеиспускания у больных доброкачественной гиперплазией простаты α-адреноблокаторами. Монография. М., 1998.
- Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92:257-61.
- Пушкарь Д.Ю., Коско Д.В., Лоран О.Б. и соавт. Опыт применения финастерида и теразосина у больных с доброкачественной гиперплазией простаты // Урология и нефрология. 1995. № 4. С. 32-35.
Supplementary files
